Multicenter Study Shows High Local Tumor Control After Resection with GammaTile in Newly Diagnosed Brain Metastases

itnonline.com · Feb 27, 2026 · Collected from GDELT

Full Article

News | Radiation Therapy | February 27, 2026 Phase IV registry data demonstrate 92.3% 12-month local control with low toxicity. Related Content Feb. 27, 2026 — A new targeted PET/CT tracer can detect treatment response in rheumatoid arthritis patients in as little ... February 26, 2026 Feb. 19, 2026 — Positrigo, a Swiss based company developing nuclear medical devices to advance functional brain imaging ... February 26, 2026 The American Society of Radiologic Technologists (ASRT) has named 109 individuals from across the country to participate ... February 24, 2026 The American Society of Radiologic Technologists (ASRT) will host a free Virtual Career Fair on March 17, from 4-7 p.m ... February 20, 2026 Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ... February 04, 2026 Jan. 29, 2026 — GE HealthCare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MIM ... February 03, 2026 Feb. 2, 2026 — GE HealthCare has announced that Allia Moveo has received U.S. Food and Drug Administration (FDA) 510(k) ... February 02, 2026 Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ... January 30, 2026 Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ... January 29, 2026 Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ... January 28, 2026